Eton Pharmaceuticals Launches IMPAVIDO in the US Market

Key Facts

1Eton Pharmaceuticals launched IMPAVIDO for leishmaniasis treatment in the US after securing exclusive commercialization rights.

Eton Pharmaceuticals launched the drug IMPAVIDO for the treatment of leishmaniasis in the United States market. Investing.com reported that the company commenced sales after securing exclusive commercialization rights and establishing the necessary distribution and patient support infrastructure known as Eton Cares.

The launch serves as a positive revenue driver for the pharmaceutical firm, providing treatment for visceral, mucosal, and cutaneous leishmaniasis. ETON closed at $57.68 on September 25, 2026, reaching a session high of $60.6 and a low of $57.23.